
Am J Psychiatry 162:802-804, April 2005
© 2005 American Psychiatric Association
Platelet Serotonin Reuptake Inhibition and Response to SSRIs in Depressed Adolescents
David A. Axelson, M.D.,
James M. Perel, Ph.D.,
Boris Birmaher, M.D.,
George Rudolph, B.S.,
Sharon Nuss, R.N.,
Linda Yurasits, B.S.,
Jeffrey Bridge, Ph.D., and
David A. Brent, M.D.
OBJECTIVE: The authors examined platelet serotonin reuptake inhibition and response to selective serotonin reuptake inhibitor (SSRI) treatment in depressed adolescents. METHOD: Twenty-three depressed adolescents participating in pharmacokinetic studies of SSRIs had platelet serotonin reuptake measured before and after 1428 days of treatment. The Clinical Global Impression (CGI) improvement rating was determined on the basis of all clinical information and was performed blind to the platelet data. RESULTS: Improvement in depressive symptoms as rated with the CGI improvement subscale was significantly associated with the percentage change in platelet serotonin reuptake inhibition from pre- to posttreatment. Improvement in depression was also associated with absolute decrease in platelet serotonin reuptake when adjusted for the magnitude of baseline reuptake. CONCLUSIONS: Platelet serotonin reuptake inhibition may be an appropriate surrogate biological marker for the pharmacodynamic activity of SSRIs in depressed adolescents.
Get information about faster international access.
a>
Privacy Policy
Copyright © 2005
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|